Omalizumab (Xolair®) increased the time to first exacerbation in patients with moderate-to-severe asthma compared with placebo

被引：0
|
作者：
O'Brien, JA
Fox, H
Thirlwell, J
机构：
[1] City Pk Med Ctr, Cape Town, South Africa
[2] Novartis Res Ctr, Horsham, W Sussex, England
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2001年 / 107卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
358
引用
收藏
页码：S107 / S107
页数：1
相关论文
共 50 条
  • [11] Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma
    Massanari, Marc
    Kianifard, Farid
    Zeldin, Robert K.
    Geba, Gregory P.
    ALLERGY AND ASTHMA PROCEEDINGS, 2009, 30 (05) : 534 - 539
  • [12] Factors predictive of response to omalizumab therapy in patients with moderate-to-severe allergic asthma
    Wenzel, S
    Bousquet, J
    Freeman, P
    Fox, H
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (01) : S156 - S156
  • [13] Incidence Of Malignancy In Omalizumab And Non-Omalizumab Treated Patients With Moderate-To-Severe Asthma: The Excels Study
    Long, A. A.
    Rahmaoui, A.
    Rothman, K. J.
    Guinan, E. C.
    Eisner, M. D.
    Bradley, M. S.
    Iribarren, C.
    Chen, H.
    Carrigan, G.
    Rosen, K.
    Szefler, S. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [14] Omalizumab: An update on efficacy and safety in moderate-to-severe allergic asthma
    Chipps, Bradley E.
    Figliomeni, Maria
    Spector, Sheldon
    ALLERGY AND ASTHMA PROCEEDINGS, 2012, 33 (05) : 377 - 385
  • [15] Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma
    Niebauer, K
    Dewilde, S
    Fox-Rushby, J
    Revicki, DA
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2006, 96 (02) : 316 - 326
  • [16] DUPILUMAB IMPROVES ASTHMA CONTROL IN PATIENTS WITH UNCONTROLLED, MODERATE-TO-SEVERE ASTHMA, REGARDLESS OF EXACERBATION HISTORY
    Corren, J.
    Castro, M.
    Maspero, J.
    Cosio, B.
    Kuna, P.
    Chen, Z.
    Staudinger, H.
    Chao, J.
    Nikhil, A.
    Ruddy, M.
    Akinlade, B.
    Graham, N.
    Teper, A.
    Khan, A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S42 - S43
  • [17] Effectiveness of omalizumab across different dosing regimens in patients with moderate-to-severe allergic asthma
    Chase, Nicole M.
    Littlejohn, Monica
    Holweg, Cecile T. J.
    Millette, Lauren A.
    Seetasith, Arpamas
    Steinke, John W.
    Trzaskoma, Benjamin L.
    Hanania, Nicola A.
    Casale, Thomas B.
    RESPIRATORY MEDICINE, 2024, 223
  • [18] Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
    Buhl, R
    Solèr, M
    Matz, J
    Townley, R
    O'Brien, J
    Noga, O
    Champain, K
    Fox, H
    Thirlwell, J
    Della Cioppa, G
    EUROPEAN RESPIRATORY JOURNAL, 2002, 20 (01) : 73 - 78
  • [19] Increased Exacerbation Burden in Allergic Polysensitized Patients with Moderate to Severe Asthma
    Patchett, Brian
    Patel, Ruchi
    Vandi, Fatima
    Mavraj, Granit
    Nriagu, Bede
    Schulman, Edward
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB116 - AB116
  • [20] Lung function trajectories in a cohort of patients with moderate-to-severe asthma on mepolizumab, omalizumab, or dupilumab
    Nopsopon, Tanawin
    Barrett, Nora A.
    Phipatanakul, Wanda
    Laidlaw, Tanya M.
    Weiss, Scott T.
    Akenroye, Ayobami
    ALLERGY, 2024, 79 (05) : 1195 - 1207
12345